Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing unique challenges, impacting the ETF’s overall ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Three stocks with yields that are less than 2% but that have been increasing their dividends at high rates in recent years ...

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...